1. Introduction

In early December 2019, several pneumonia cases of unknown origin were observed in Wuhan (China). A novel enveloped RNA \( \beta \) coronavirus was isolated and named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The new virus rapidly spread across China and worldwide. On March 11th, 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic [2]. As of December 27, 2020, COVID-19 has been confirmed in over 79.2 million individuals globally with deaths reaching 1.75 million with a mortality of 2.2%. Egypt has 131,315 confirmed cases and 7352 deaths [3].

The virus mainly spreads through respiratory droplets from infected patients [4]. The clinical spectrum of COVID-19 infection ranges from asymptomatic forms to severe pneumonia requiring hospitalization and isolation in critical care units with the need of mechanical ventilation due to acute respiratory distress syndrome (ARDS). Severe COVID-19 conditions are usually due to an aggressive inflammatory response known as cytokine storm (CS) that is characterized by the release of a large amount of pro-inflammatory cytokines [5,6]. Treating this cytokine storm state improves morbidity and mortality [7]. Immunomodulators, cytokine antagonists, and cytokine removal are potential options to manage cytokine storm [8].

Therapeutic plasma exchange (TPE) removes pro-inflammatory cytokines mediating cytokine storm condition. TPE had been used successfully in severe H1N1 influenza A infection [9]. Steroids are the most used drug to treat cytokine storm of COVID-19. Tocilizumab [interleukin (IL) 6 antagonist] also is used widely with promising results. But a considerable percentage of patients do not respond to it leaving physicians with very limited options and usually patients deteriorate rapidly with very high mortality. Hence, we decided to test the efficacy of TPE in those patients who did not respond to tocilizumab.

CONTACT Mohamed Mamdouh Elsayed, Montasser Mohamed Zeid, Akram Mohamed Fayed, Ehab Mahmoud Elreweny, Nermine Hossam Zakaria and Ayman Ibrahim Baess

*Nephrology and Internal Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt; †Critical Care Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt; ‡Clinical and Chemical Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt; §Chest Diseases Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

Does therapeutic plasma exchange have a role in resistant cytokine storm state of COVID-19 infection?

Mohamed Mamdouh Elsayed, Montasser Mohamed Zeid, Akram Mohamed Fayed, Ehab Mahmoud Elreweny, Nermine Hossam Zakaria and Ayman Ibrahim Baess

ABSTRACT

Introduction: Among the main causes of mortality in COVID-19 patients is cytokine storm (CS) state. Few treatment options with variable efficacy results are available for its management. We aimed to illustrate the efficacy of Therapeutic Plasma Exchange (TPE) treatment in COVID-19 patients with resistant CS.

Material and methods: This research is a prospective pilot study which included ten COVID-19 positive patients with CS state with no response after two doses of tocilizumab. Each patient received three to five TPE sessions according to his/her response. Respiratory status (oxygen \( O_2 \) requirements and data of mechanical ventilation) and laboratory markers (IL-6, CRP, ferritin, D dimer, LDH) were assessed before and after TPE. We reported mortality at 28 days of illness.

Results: Six males and four females were enrolled in the study with a mean age of (52.9 years). Seven patients (70%) were on mechanical ventilation (MV). After TPE, oxygenation parameters and most laboratory markers improved significantly in all patients (p < 0.05). Four patients survived and were discharged (40%). One was on MV and three were not. The four patients had better hypoxic index (PaO2/FiO2 ratio) (>100 vs <100), started TPE sooner after tocilizumab failure (2–3 vs 5–6 days), needed fewer TPE sessions (3 vs 4–5, p = 0.03), and less duration in ICU (6.5 vs 12.5 days) compared to those who did not benefit.

Conclusions: In patients with CS state who did not respond well to tocilizumab and steroids, TPE could be a good option. Larger randomized clinical trials are needed to support its use.

Clinical trials registration: ClinicalTrials.gov Identifier:NCT04457349

ARTICLE HISTORY

Received 2 July 2021
Accepted 24 September 2021

KEYWORDS

COVID-19; cytokine storm; therapeutic plasma exchange; TPE

https://doi.org/10.1080/20905068.2021.1987111

OPEN ACCESS

Check for updates
2. Patients and methods

2.1. Participants

This research included 10 patients from the COVID-19 isolation hospitals in Alexandria, Egypt who had CS state with no improvement after two doses of tocilizumab. Criteria of failure (resistance) of tocilizumab were: persistent high IL-6 and C reactive protein (CRP), persistent worsening of respiratory symptoms (dyspnea, tachypnea, increased oxygen (O₂) requirements or even need for mechanical ventilation), partial arterial pressure of oxygen to fractional inspired concentration of oxygen (PaO₂/FiO₂) ratio <150, persistent fever (>38.5°C) despite normal procalcitonin level. Patients with refractory septic shock were excluded. Patients were treated according to the COVID-19 management protocol of the Egyptian ministry of health [10]. The study protocol was approved by the medical ethics committee in our hospital. This research was conducted in accordance with the ethical guidelines of the Declaration of Helsinki and informed consent was obtained from each patient. In unconscious patients, consent was obtained from legal guardians.

2.2. Methods and study outcomes

All patients were subjected to full history taking, full clinical examination, assessment of oxygen (O₂) requirements, and data of mechanical ventilation. Laboratory investigations included serum IL-6, complete blood picture (CBC) including lymphocytic and neutrophilic counts, erythrocyte sedimentation rate (ESR), CRP, Lactate dehydrogenase (LDH), ferritin, D-dimer, procalcitonin, serum albumin, blood urea, serum creatinine, liver enzymes, sodium, potassium, calcium, PT, PTT, INR. Chest x-ray, computed tomography (CT) chest were used to assess lung affection.

TPE was done through filtration technique using a plasma filter (Plasmart 600, Medica company, Italy) at a dose of (1-1.5) plasma volume/session. Fresh frozen plasma or albumin 5% was used to replace plasma. Each patient received two to five sessions according to their response. Clinical, laboratory and radiological parameters were assessed before and after TPE.

Primary outcome was to assess 28-day mortality. Secondary outcomes included changes in oxygenation parameters, clinical status and laboratory markers of CS condition.

2.3. Statistical analysis

Data were analyzed using IBM SPSS version 22. Data were presented as range, median, and inter-quartile range for quantitative variables and number and percentage for qualitative variables. Paired comparisons as regard quantitative variables were conducted using Wilcoxon-signed rank test at 5% level of significance.

3. Results

3.1. Baseline characteristics of patients

This research enrolled 10 patients with a mean age of 52.90 ± 10.48 years ranging from 37 to 68 years. Sixty percent of studied patients were males. The majority were having a chronic disease or obese. Seven patients (70%) were on mechanical ventilation (MV), two (20%) patients were on mask reservoir, one (10%) patient was on high flow nasal cannula.

3.2. Clinical course, laboratory parameters, and mortality before and after TPE

After TPE, oxygenation parameters (O₂ requirements and data of mechanical ventilation) and most of laboratory markers (IL-6, ferritin, LDH, and D dimer) improved significantly in all patients (p < 0.05). In addition, CRP and lymphocytic count improved after TPE but not significantly with p value of 0.093 and 0.074, respectively (Table 1). Regarding clinical outcome assessed by 28-day mortality, six patients (60%) died and four patients (40%) survived and discharged. All patients on mechanical ventilation (MV) had severe ARDS (100%). Patients who survived (4/10) (3 without MV and 1 on MV), had better hypoxic index (PaO₂/FiO₂ ratio) (>100 vs <100), started TPE sooner after tocilizumab failure (2–3 vs 5–6 days), needed fewer TPE sessions (3 vs 4–5, p = 0.03) and less duration in ICU (6.5 vs 12.5 days) compared to those who did not benefit. From mechanically ventilated patients (7), only one (15%) was extubated 2 days after TPE. Regarding TPE safety, one patient suffered from bradycardia during one session near its end. Full data for each patient regarding demographic, laboratory parameters, oxygenation data, and clinical outcomes before and after TPE are shown in Table 2.

4. Discussion

COVID-19 pandemic has affected the whole world due to very rapid spread of the virus in communities causing many deaths. A lot of health sectors have
promising with IP-10, many of mechanical tion. Two have respond variable used effects way severe collapsed – [11-13].

1. Clear and the described in PaO₂. Serum IL-6 Parameter x p C.R.P. patients A Min-Max Median±IQR Median±IQR Median±IQR Min-Max Min-Max Median±IQR Min-Max Median±IQR Serum ferritin (ng/ml) 833–1674 1258(927–1477) Lymphocytic count (10⁹/l) 0.3–1.3 0.65(0.47–1.05) C.R.P (mg/l) 53–261 148(75–203) PaO₂/FI O₂ ratio 57–144 90(71–111) Median±IQR Median±IQR Median±IQR Median±IQR Median±IQR Median±IQR Median±IQR Median±IQR

Data were expressed in range and median (Min.-Max.).

*: Statistically significant at p ≤ 0.05.

CRP: C-reactive protein, IL 6: interleukin 6, LDH: lactate dehydrogenase, PaO₂/FI O₂: Partial arterial pressure of oxygen to fractional inspired concentration of oxygen.

collapsed due to shortage of critical care beds and mechanical ventilators compared to the huge number of patients with severe disease. This health catastrophe has led the worldwide economy to go down. An increasing number of vaccines against COVID-19 infection got the approval to be used in many countries hoping to provide immunity and limit number of severe infections.

One of the main causes of death from COVID-19 infection is CS state with disproportionate rise in many cytokines like IL-6, IL-2, IL-7, IL-10, G-CSF, IP-10, MCP-1, MIP-1A, and TNF-α that correlated with the disease severity [1,11]. So, attacking this pathway was a target by scientists to prevent the deleterious effects of this immune dysregulation. The most widely used drugs were corticosteroids and tocilizumab with variable efficacy.

A considerable percentage of patients do not respond to these drugs opening the gate for cytokine removal strategies like TPE to be used. Some have used TPE from the start [12] and others tried it after failure of other options [13] with very promising results.

In our study, we started TPE only after failure of two doses of tocilizumab to improve disease condition. Oxygenation status (O₂ requirements and PaO₂/FI O₂ ratio) and laboratory markers improved in all patients (100%). This finding had been described in recently published data [14–16]. But the reflection of that clear improvement (clinically and serologically) on patient mortality was not clearly identified with 40% survived and 60% died at 28 day of illness.

Analyzing our data, we found that patients who lived (n = 4) 3 patients not on MV and one mechanically ventilated, had moderate ARDS and started TPE earlier than others. Non mechanically ventilated patients had obvious clear benefit on 28-day mortality (0 vs 85%) compared to patients on MV. In contrast to our mortality data on MV patients, Khamis et al. [17] in their study which included 31 patients with severe COVID-19 infection found that patients on TPE had a lower 14 days (0 vs 35%; p = 0.033) and 28 days (0 vs 35%; p = 0.033) post plasma exchange mortality compared to patients not on TPE. However, all-cause mortality was only marginally lower in the TPE group compared to the non-TPE group (9.1% vs 45%; p = 0.055). Similar results had been described by others [13,18].

The explanation for higher mortality rates in our patients on MV compared to others might be the delayed start of TPE and longer duration on MV before beginning TPE therapy in our cohort waiting the failure of tocilizumab use, so the chest condition became worse. What support this hypothesis is that 100% of our patients who were not on MV survived and discharged and the patient on MV who survived started TPE after 1 day of intubation.

Considering TPE safety, bradycardia occurred in one patient at the end of session and improved within one hour. But none had suffered from hypotension, cramps, nor bleeding events reflecting safety of this procedure.

The main cause of death in most patients was respiratory failure. Septic shock in one patient.
Table 2. Individual patient’s data regarding demographic, laboratory parameters, oxygenation data, and clinical outcomes before and after TPE.

| Patient no. | Age (ys) | Sex | Medical history | IL 6 (pg/ml) Pre | IL 6 (pg/ml) Post | Ferritin (ng/ml) Pre | Ferritin (ng/ml) Post | D dimer (ng/ml) Pre | D dimer (ng/ml) Post | CRP (mg/l) Pre | CRP (mg/l) Post | LDH (u/l) Pre | LDH (u/l) Post | Lymphocytic count ($10^9$/l) Pre | Lymphocytic count ($10^9$/l) Post | TPE sessions (No) | Respiratory status | (PaO₂/FiO₂) ratio | ICU stay (days) | 28-day mortality |
|-------------|----------|-----|-----------------|------------------|------------------|---------------------|---------------------|-------------------|-------------------|---------------|---------------|-------------|-------------|---------------------|---------------------|----------------|-------------------|-----------------|------------------|------------------|
| 1           | 54       | M   | HTN             | 340              | 116              | 1189                | 332                 | 2410              | 1382             | 76            | 21            | 923          | 723         | 0.6                  | 0.7                 | 4               | MV               | PEEP 8          | 88              | 170            | Died            |
| 2           | 49       | M   | DM              | 250              | 2.3              | 1477                | 730                 | 1230              | 902              | 45            | 4            | 563          | 307         | 0.7                  | 1.2                 | 3               | Mask Reservoir 8 l/min | MV, PEEP 12 | PEEP 8         | 130             | 264            | 7               | Survived        |
| 3           | 63       | F   | Asthmatic       | 115              | 7.3              | 1356                | 857                 | 836               | 573              | 34           | 124          | 245          | 220         | 1.3                  | 0.8                 | 4               | MV, PEEP 15 | MV, PEEP 14 | PEEP 10 | 73             | 135             | 14             | Died            |
| 4           | 38       | M   | free            | 637              | 26              | 882                 | 345                 | 692               | 471              | 212          | 18          | 671          | 421         | 0.5                  | 1.3                 | 4               | MV, PEEP 14 | PEEP 8          | 66              | 111            | 13             | Died            |
| 5           | 51       | F   | HTN, obese      | 316              | 32              | 833                 | 376                 | 1378              | 838              | 53           | 124          | 783          | 603         | 1.2                  | 0.9                 | 5               | MV, PEEP 10 | Mask Reservoir 8 l/min | MV, PEEP 10 | MV, PEEP 10 | PEEP 6 | 92             | 155             | 12             | Died            |
| 6           | 48       | F   | Free            | 289              | 19.4            | 1479                | 662                 | 349               | 156              | 75           | 11           | 854          | 434         | 0.9                  | 1.2                 | 3               | Mask Reservoir 8 l/min | MV, PEEP 8 | MV, PEEP 14 | Nasal Cann 4 l/min | 144           | 270            | 5               | Survived        |
| 7           | 64       | M   | DM, HTN         | 78               | 5               | 942                 | 285                 | 943               | 632              | 125          | 24           | 669          | 311         | 0.4                  | 1.4                 | 4               | MV, PEEP 10 | Extubated       | 85              | 255            | 10             | Survived        |
| 8           | 57       | F   | Obese, IHD      | 569              | 6.3             | 1293                | 466                 | 444               | 238              | 261          | 29           | 779          | 476         | 1                   | 1.7                 | 3               | MV, PEEP 8 | High flow Nasal Cann | MV, PEEP 10 | MV, PEEP 10 | Nasal Cann 5 l/min | 105           | 292            | 6              | Survived        |
| 9           | 68       | M   | IHD             | 167              | 12              | 1224                | 338                 | 878               | 983              | 179          | 141          | 692          | 612         | 0.3                  | 0.7                 | 4               | MV, PEEP 8 | PEEP 14         | 57              | 86             | 10             | Died            |
| 10          | 37       | M   | Dyslipidemic    | 57               | 45              | 1674                | 1314                | 723               | 544              | 122          | 264          | 828          | 446         | 0.6                  | 0.75                | 5               | MV, PEEP 18 | MV, PEEP 14     | 95              | 121            | 11             | Died            |

DM: diabetes mellitus, F: female, HTN: hypertension, ICU: intensive care unit, IHD: ischemic heart disease, M: male, MV: mechanical ventilation, nasal cann.: nasal cannula, PEEP: positive end-expiratory pressure, TPE: therapeutic plasma exchange.
The main limitation of our study is the small sample size (n = 10), but it revealed promising results on TPE use.

5. Conclusion
In patients with CS state who did not respond well to tocilizumab and steroids, TPE could be a good option. Larger randomized clinical trials are needed to support the evidence of TPE efficacy in resistant cytokine storm conditions complicating COVID-19 infection.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Notes on contributors
Mohamed Mamdouh Elsayed is a lecturer of nephrology & internal medicine.
Montasser Mohamed Zeid is a professor of nephrology & internal medicine.
Akram Mohamed Fayed is a professor of critical care medicine.
Ehab Mahmoud Elreweny is a professor of critical care medicine.
Nermine Hossam Zakaria is a professor of clinical and chemical pathology.
Ayman Ibrahim Baess is an assistant professor of chest diseases.

ORCID
Mohamed Mamdouh Elsayed http://orcid.org/0000-0001-7656-7116
Akram Mohamed Fayed http://orcid.org/0000-0001-6991-4407

References
[1] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
[2] WHO. Coronavirus disease 2019 (COVID-19) Situation Report 52. 2020.
[3] WHO. Coronavirus disease 2019 (COVID-19) Weekly epidemiological update; 2020 December 29.
[4] Chan J, Yuan S, Kok K, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523.
[5] Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848.
[6] Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629.
[7] Ragab D, Salah Eldin H, Taemah M, et al. COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.
[8] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J Infect. 2020;80(6):607–613.
[9] Patel P, Nandwani V, Vanchiere J, et al. Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A–an associated respiratory failure and hemodynamic shock. Pediatr Crit Care Med. 2011;12(2):e87–9.
[10] Masoud H, Elassal G, Hassany M, et al. Management Protocol for COVID-19 Patients MoHP Protocol for COVID19 November 2020; 2020.
[11] Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.
[12] Gluck WL, Gallahan SP, Breevetta RA, et al. Efficacy of therapeutic plasma exchange in the treatment of Penn class 3 and 4 cytokine release syndrome complicating COVID-19. Resp Med. 2020;175:106188.
[13] Adeli SH, Ashgari A, Tabarraii R, et al. Therapeutic plasma exchange as a rescue therapy in patients with coronavirus disease 2019: a case series. Pol Arch Intern Med. 2020;130(5):455–458.
[14] Zhang L, Zhai H, Ma S, et al. Efficacy of therapeutic plasma exchange in severe COVID 19 patients. Br J Haematol. 2020;190(4):181–183.
[15] Sarfraz A, Makkar SS, Sarfraz Z, et al. Therapeutic plasma exchange and COVID 19: a rapid review. J Clin Immunol Immunoother. 2020;6:041.
[16] Shi H, Zhou C, He P, et al. Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19. Int J Antimicrob Agents. 2020;56(2):105974.
[17] Khamis F, Al-Zakwani I, Al Hashmi S, et al. Therapeutic plasma exchange in adults with severe COVID 19 infection. Int J of Infect Dis. 2020;99:214–218.
[18] Keith P, Day M, Perkins L, et al. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care. 2020;24(1):128.